

The Forum for Collaborative HIV Research
HCV Drug Resistance Advisory Group
Sheraton Premier at Tysons Corner
Vienna, VA
May 18, 2007

Charles Boucher, M.D., Ph.D.
Universitair Medical Center

Scott Bowden, Ph.D.
Victorian Infectious Diseases Reference Laboratory

Ben Cheng, M.Sc.
Forum for Collaborative HIV Research

Joe Fitzgibbon, Ph.D.
NIH / NIAID / DAIDS

Jennifer Hammond, Ph.D.
Pfizer Global Research and Development

Daria Hazuda, Ph.D.
Merck & Co., Inc.

Anita Howe, Ph.D.
Wyeth Research

Dale Kempf, Ph.D.
Abbott

Tara Kieffer, Ph.D.
Vertex Pharmaceuticals, Inc.

George Kukolj, B.Sc., Ph.D.
Boehringer Ingelheim (Canada) Ltd. R&D

Ann Kwong, Ph.D.
Vertex Pharmaceuticals, Inc.

Kai Lin, Ph.D.
Novartis

Meagan Lyon, M.P.H.
Forum for Collaborative HIV Research

Veronica Miller, Ph.D.
Forum for Collaborative HIV Research

Hongmei Mo, M.D.
Gilead Science

Isabel Najera, Ph.D.
Roche Palo

Linda Onaga, M.P.H.
Forum for Collaborative HIV Research

Jules O'Rear, Ph.D.
FDA / CDER / OND / OAP/ Division of Antiviral Products

Michael Otto, Ph.D.
Pharmasset Inc.

Neil Parkin, Ph.D.
Monogram Biosciences

Jean-Michel Pawlotsky, M.D., Ph.D.
Hopital Henri Mondor

Gaston Picchio
Tibotec, Inc.

Tami Pilot-Matias, Ph.D.
Abbott

Robert Ralston, Ph.D.
Schering-Plough Corp.

Douglas D. Richman, M.D.
University of California, San Diego

Robert T. Schooley, M.D.
University of California, San Diego

David N. Strandring, Ph.D.
Idenix Pharmaceuticals, Inc.

Lieven Stuyver, Ph.D.
Virco bvba

David Williams
MedPharma Partners LLC